

Synthesis and Inhibitory Activities of Isochromophilone Analogues against gp120-CD4 Binding

XUE-LONG SUN, HIROAKI TAKAYANAGI*, KEIICHI MATSUZAKI,
HARUO TANAKA and KIMIO FURUHATA

School of Pharmaceutical Sciences, Kitasato University,
5-9-1 Shirokane, Minato-ku, Tokyo 108, Japan

SATOSHI ŌMURA

Research Center for Biological Function, The Kitasato Institute,
5-9-1 Shirokane, Minato-ku, Tokyo 108, Japan

(Received for publication March 11, 1996)

Several isochromophilone analogues were synthesized from sclerotiorin (**1**) by Wittig reactions and aldol condensation reaction. The structures of the products were elucidated from MS, elemental analysis, ^1H NMR and ^{13}C NMR spectra, and their inhibitory activities against gp120-CD4 binding were determined.


Sclerotiorin (**1**) occurs as a major metabolite in several species of monovercillate *Penicillia*.¹⁾ It was first isolated from a culture of *Penicillium* Van Beyma by CURTIN and REILLY.²⁾ Recently, in the screening program for new inhibitors against gp120-CD4 binding from microorganisms, isochromophilones Ia (**2**) and IIa (**3**), which have the same azaphilone skeleton and chlorine as **1**, were found as novel non-peptide inhibitors from a culture broth of *Penicillium* sp. FO-2338^{3,4)} (Chart 1). Although **1** was also found to be produced abundantly by the strain, its inhibitory activity against gp120-CD4 binding was much less than that of **2** and **3**. In order to understand the relationship between the structure and activity, we selected **1** as starting material to synthesize several derivatives, and determined their inhibitory activities against gp120-CD4 binding.

Results


The comparison of the structures of sclerotiorin (**1**) with isochromophilone Ia (**2**) and isochromophilone IIa (**3**) suggested that the 7-*O*-group and carbon-8 may be the groups principally responsible for the inhibitory

activities. In order to prove this, at first, we tried the Wittig reaction at 8-carbonyl group of **1** with carbethoxymethylene-triphenylphosphorane. However, we didn't succeed by using **1** as starting material directly, so we performed the basic hydrolysis of the 7-*O*-acetyl group of **1** with sodium methoxide in refluxing methanol to obtain **4** in 89% yield. From **4** we obtained an olefinic ester **5** in 70% yield. The structure of **5** was elucidated from MS and ^1H NMR data. In ^1H NMR, the characteristic signal of the new product is the new olefinic proton (6.59 ppm, s, 10-H) and *O*-ethyl group (4.15 ppm, m, CH_2 ; 1.20 ppm, t, $J=7.8$ Hz, CH_3). The seqcis conformation of the new olefin of **5** was determined by NOE experiment between H-1 and H-10 (2%). Treatment of **4** with the Wittig agent 1-triphenylphosphoranylidene-2-propanone gave **6** in 30% yield. **5** was acetylated by acetic anhydride in pyridine at room temperature to yield **7** in 91%. Compound **8** was synthesized from **5** under basic condition by intramolecular esterification in 85% yield. The structure was elucidated by MS, ^1H NMR data, H-10 showed at 5.99 ppm (s), and NOE between H-1 and H-10 was approximately 5%.


Chart 1.



Scheme 1.



Scheme 2.



To synthesize rubrorotiorin (**9**),²⁾ we conducted an intermolecular esterification reaction between **4** and diketene, and then an intramolecular aldol condensation reaction of the above product (Scheme 2). From this reaction **10** was also obtained as by-product in 3% yield. The structure of these products were elucidated by MS, ¹H NMR, ¹³C NMR data, HMBC, HMQC and NOE. For the above products **5**, **6**, **7**, **8** and **9**, we conducted selective reduction of C-8, C-10 olefin as α,β -unsaturated carbonyl compounds with Birch reduction or sodium hydrogen telluride reduction reagent,^{5,6)} but didn't succeed. It may be due to several olefin bonds and lactone structure in these compounds are unstable to these reduction conditions.

The inhibitory activities against gp120-CD4 binding of these products were determined. Table 1 shows that compounds **5**, **8** and **9** inhibited gp120-CD4 binding with IC₅₀ of 2.6, 8.1, and 13 $\mu\text{g/ml}$, respectively. These values rank with those of **2** and **3** (IC₅₀: 2.75 and 1.51 $\mu\text{g/ml}$, respectively). Compound **4** exhibited weaker inhibition (IC₅₀: 39 $\mu\text{g/ml}$), but compound **10** exhibited no inhibition at more than 100 $\mu\text{g/ml}$.

In conclusion, we have selected **1** as starting material to synthesize several isochromophilone analogues, and determined their inhibitory activities against gp120-CD4

Table 1. Inhibitory activities against gp120-CD4 binding.

Compounds	IC ₅₀ ($\mu\text{g/ml}$)
1	> 100
2	2.75
3	1.51
4	39
5	2.60
8	8.10
9	13
10	> 100

binding. These results suggested that 7-hydroxyl group may be effective for the inhibition, but 8-carbonyl group may be not. Further studies will be reported later.

Experimental

General Procedures

Melting points were measured on a Yamato melting point apparatus and not corrected. Fast atom bombardment mass spectra (FAB-MS) were taken on JEOL JMS-DX 300. IR spectra were obtained on a Perkin-Elmer 983G Infrared spectrometer. The ¹H NMR spectra were determined with a Varian VXR-300 and XL-400 spectrometers, in the solvent state, with tetramethyl-

silane (TMS) as an internal reference. Thin layer chromatography (TLC) was performed on kiesel gel 60F₂₅₄ (Merck) plates, and spots were detected by ultraviolet (UV) and by spraying with 5% sulfuric acid solution. Column chromatography was conducted on silica gel 60 (70~230 mesh) (Merck).

7-Hydroxy-5-chloro-3-(3,5-dimethyl-1,3-heptadienyl)-7-methyl-6*H*-2-benzopyran-6,8(7*H*)-dione (**4**): **1** (500 mg, 1.30 mmol) was dissolved in anhydr. MeOH (100 ml), and NaOMe (70 mg, 1.26 mmol) was added. The solution was refluxed at 80°C for 5 hours, until no more starting material was found by TLC (*n*-hexane:acetone 3:1). Then the reaction solution was cooled to room temperature, and gradually acidified with Dowex 50w-1 (H⁺) cation-exchange resin to pH 7~7.5. The resin was filtered and washed twice with MeOH. The filtrate was evaporated to dryness *in vacuo*, and purified by silica gel column chromatography (*n*-hexane:acetone 3:1) to yield **4** (400 mg, 89%).

4: Yellow powder, mp: 80~82°C, FAB-MS *m/z*: 349 (M+1)⁺ (*m*-NBA as matrix), *Anal* Calcd for C₁₉H₂₁O₄Cl: C 65.51, H 6.03, Cl 10.06. Found: C 65.29, H 6.01, Cl 9.72. ¹H NMR (300 MHz, CDCl₃) δ 0.86 (3H, t, *J*=7.8 Hz, 7'-CH₃), 1.05 (3H, d, *J*=7.2 Hz, 9'-CH₃), 1.30 (1H, m, 6'-H), 1.44 (1H, m, 6'-H), 1.58 (3H, s, 9-CH₃), 1.84 (3H, s, 8'-CH₃), 2.48 (1H, m, 5'-H), 3.80 (1H, br s, 7-OH), 5.73 (1H, d, *J*=10.2 Hz, 4'-H), 6.08 (1H, d, *J*=15.6 Hz, 1'-H), 6.62 (1H, s, 4-H), 7.09 (1H, d, *J*=15.6 Hz, 2'-H), 7.93 (1H, s, 1-H).

5-Chloro-3-(3,5-dimethyl-1,3-heptadienyl)-7-hydroxy-7-methyl-8-(ethoxycarbonylmethyliden)-6*H*-2-benzopyran-6-one (**5**): **4** (400 mg, 1.15 mmol) was dissolved in anhydr. ether (30 ml), and Ph₃P=CHCOOC₂H₅ (446 mg, 1.28 mmol) was added. The solution was stirred at room temperature for 5 hours, until no more starting material was found by TLC (*n*-hexane:acetone 3:1). The solution was evaporated to dryness *in vacuo*. The residue was purified by silica gel column chromatography (*n*-hexane:acetone 3:1) to yield **5** (340 mg, 70%).

5: Yellow powder, mp: 155~157°C, FAB-MS *m/z*: 419 (M+1)⁺ (*m*-NBA as matrix), *Anal* Calcd for C₂₃H₂₇O₄Cl: C 66.03, H 6.46, Cl 8.37. Found: C 65.71, H 6.69, Cl 8.27. ¹H NMR (300 MHz, CDCl₃) δ 0.85 (3H, t, *J*=7.8 Hz, 7'-CH₃), 1.05 (3H, d, *J*=7.2 Hz, 9'-CH₃), 1.20 (3H, t, *J*=7.8 Hz, 10-COOC₂H₅CH₃), 1.28 (2H, m, 6'-H₂), 1.44 (3H, s, 9-CH₃), 1.83 (3H, s, 8'-CH₃), 2.47 (1H, m, 5'-H), 4.15 (2H, m, 10-COOC₂H₅CH₃), 4.27 (1H, br s, 7-OH), 5.66 (1H, d, *J*=10.2 Hz, 4'-H), 6.08 (1H, d, *J*=15.6 Hz, 1'-H), 6.59 (H, s, 10-H), 7.08 (1H, d, *J*=15.6 Hz, 2'-H), 8.07 (1H, s, 1-H).

5-Chloro-3-(3,5-dimethyl-1,3-heptadienyl)-7-hydroxy-7-methyl-8-(2-oxo-propyliden)-6*H*-2-benzopyran-6-one (**6**): **4** (300 mg, 0.862 mmol) was dissolved in anhydr. ether (30 ml), and Ph₃P=CHCOCH₃ (411 mg, 1.28 mmol) was added. The mixture was processed as described for **5** to yield **6** (87 mg, 30%).

6: Yellow powder, mp: 140~141°C, FAB-MS *m/z*:

389 (M+1)⁺ (*m*-NBA as matrix), *Anal* Calcd for C₂₂H₂₅O₄Cl: C 68.04, H 6.44, Cl 9.02. Found: C 68.45, H 6.26, Cl 9.09. ¹H NMR (300 MHz, CDCl₃) δ 0.86 (3H, t, *J*=7.8 Hz, 7'-CH₃), 1.00 (3H, d, *J*=7.2 Hz, 9'-CH₃), 1.34 (2H, m, 6'-H₂), 1.44 (3H, s, 8-CH₃), 1.83 (3H, s, 8'-CH₃), 2.26 (3H, s, 10-COCH₃), 2.47 (1H, m, 5'-H), 4.32 (1H, br s, 7-OH), 5.68 (1H, d, *J*=10.2 Hz, 4'-H), 6.07 (1H, d, *J*=15.6 Hz, 1'-H), 6.57 (H, s, 10-H), 7.09 (1H, d, *J*=15.6 Hz, 2'-H), 8.27 (1H, s, 1-H).

5-Chloro-3-(3,5-dimethyl-1,3-heptadienyl)-7-acetyloxy-7-methyl-8-(ethoxycarbonylmethyliden)-6*H*-2-benzopyran-6-one (**7**): To a solution of **5** (100 mg, 0.24 mmol) in pyridine (20 ml), acetic anhydride (122 mg, 1.20 mmol, 5 eq) was added. The mixture was stirred at room temperature for 12 hours. The solution was poured into 0.5 N HCl aq. (20 ml), extracted with EtOAc (30 ml × 3), the extract was washed with saturated NaHCO₃ aq. and brine, dried with anhydrous Na₂SO₄, concentrated to dryness, and purified by silica gel column chromatography (*n*-hexane:acetone 5:1) to yield **7** (100 mg, 91%).

7: Yellow amorphous, FAB-MS *m/z*: 461 (M+1)⁺ (*m*-NBA as matrix), *Anal* Calcd for C₂₅H₂₉O₅Cl: C 65.22, H 6.30, Cl 7.72. Found: C 65.10, H 6.42, Cl 7.90. ¹H NMR (300 MHz, CDCl₃) δ 0.84 (3H, t, *J*=7.8 Hz, 7'-CH₃), 0.99 (3H, d, *J*=7.2 Hz, 9'-CH₃), 1.24 (3H, t, *J*=7.8 Hz, 10-COOC₂H₅CH₃), 1.35 (2H, m, 6'-H₂), 1.54 (3H, s, 9-CH₃), 1.81 (3H, s, 8'-CH₃), 2.17 (3H, s, 7-OAc), 2.45 (1H, m, 5'-H), 4.14 (2H, m, 10-COOC₂H₅CH₃), 5.63 (1H, d, *J*=10.2 Hz, 4'-H), 5.85 (H, s, 10-H), 6.05 (1H, d, *J*=15.0 Hz, 1'-H), 6.51 (H, s, 4-H), 7.02 (1H, d, *J*=15.0 Hz, 2'-H), 8.12 (1H, s, 1-H).

5-Chloro-3-(3,5-dimethyl-1,3-heptadienyl)-6*a*-methyl-6*H*-furo[2,3-*h*]-2-benzopyran-6,8(6*aH*)-dione (**8**): **5** (330 mg, 0.79 mmol) was dissolved in anhydr. MeOH (50 ml), and NaOMe (158 mg, 1.54 mmol, 2 eq) was added. The solution was stirred at room temperature for 1 hour, until no more starting material was found by TLC (*n*-hexane:acetone 3:1). Then the solution was gradually acidified with Dowex50w-1(H⁺) cation-exchange resin to pH 7~7.5. The resin was filtered and washed twice with MeOH. The filtrate was evaporated to dryness *in vacuo*, and purified by silica gel column chromatography (*n*-hexane:acetone 4:1) to yield **8** (250 mg, 85%).

8: Yellow amorphous, FAB-MS *m/z*: 373 (M+1)⁺ (*m*-NBA as matrix), *Anal* Calcd for C₂₁H₂₁O₄Cl: C 67.74, H 5.65, Cl 9.41. Found: C 67.82, H 5.57, Cl 9.70. ¹H NMR (300 MHz, CDCl₃) δ 0.87 (3H, d, *J*=7.8 Hz, 7'-CH₃), 1.02 (3H, d, *J*=7.2 Hz, 9'-CH₃), 1.34 (1H, m, 6'-H), 1.44 (1H, m, 6'-H), 1.67 (3H, s, 9-CH₃), 1.85 (3H, s, 8'-CH₃), 2.48 (1H, m, 5'-H), 5.71 (1H, d, *J*=10.2 Hz, 4'-H), 5.99 (1H, s, 10-H), 6.09 (1H, d, *J*=15.6 Hz, 1'-H), 6.58 (1H, s, 4-H), 7.08 (1H, d, *J*=15.6 Hz, 2'-H), 7.63 (1H, s, 1-H).

9-Acetyl-5-chloro-3-(3,5-dimethyl-1,3-heptadienyl)-6*a*-methyl-6*H*-furo[2,3-*h*]-2-benzopyran-6,8(6*aH*)-dione (**9**): **4** (715 mg, 2.05 mmol) was dissolved in THF

(50 ml), Diketene (345 mg, 4.1 mmol, 2 eq) and DMAP (20 mg, 0.16 mmol, 2 eq) were added. The solution was stirred at room temperature for 5 hours, until no more starting material was found by TLC (*n*-hexane:acetone 3:1). The reaction solution was evaporated to dryness *in vacuo*, and purified by silica gel column chromatography (*n*-hexane:acetone 4:1) to yield **9** (460 mg, 54%) and 3,7-diacetyl-6-chloro-5-(2-oxo-5,7-dimethyl-3,5-nonadienyl)-9a-methyl-2*H*-furo[2,3-*h*]-1-benzopyran-2,8-dione (**10**) (28 mg, 3%).

9: Yellow amorphous, FAB-MS *m/z*: 415 (*M*+1)⁺ (*m*-NBA as matrix), Anal Calcd for C₂₃H₂₄O₅Cl: C 66.67, H 5.80, Cl 8.45. Found: C 66.87, H 6.09, Cl 8.24. ¹H NMR (300 MHz, CDCl₃) δ 0.87 (3H, d, *J*=7.6 Hz, 7-CH₃), 1.03 (3H, d, *J*=7.2 Hz, 9'-CH₃), 1.32 (1H, m, 6'-H), 1.45 (1H, m, 6'-H), 1.72 (3H, s, 9-CH₃), 1.87 (3H, s, 8'-CH₃), 2.48 (1H, m, 5'-H), 2.60 (3H, s, 10-COCH₃), 5.74 (1H, d, *J*=9.2 Hz, 4'-H), 6.09 (1H, d, *J*=14.8 Hz, 1'-H), 6.63 (1H, s, 4-H), 7.13 (1H, d, *J*=14.8 Hz, 2'-H), 8.84 (1H, s, 1-H). ¹³C NMR (75 MHz, CDCl₃) δ 11.928 (7'-C), 12.353 (8'-C), 20.151 (9'-C), 26.333 (9-C), 29.694 (6'-C), 30.035 (10-COCH₃), 30.081 (5'-C), 87.551 (7-C), 105.636 (4-C), 110.241 (1a-C), 115.627 (1'-C), 123.789 (10-C), 131.997 (3'-C), 139.530 (4a-C), 143.611 (2'-C), 149.384 (4'-C), 152.008 (1-C), 158.024 (3-C), 163.721 (8-C), 167.721 (5-C), 182.215 (10-COCH₃), 183.072 (6-C), 194.277 (11-C).

10: Yellow amorphous, FAB-MS *m/z*: 455 (*M*+1)⁺ (*m*-NBA as matrix). ¹H NMR (300 MHz, CDCl₃) δ 0.86 (3H, d, *J*=7.6 Hz, 7-CH₃), 1.02 (3H, d, *J*=7.2 Hz, 9'-CH₃), 1.32 (1H, m, 6'-H), 1.44 (1H, m, 6'-H), 1.83 (3H, s, 8'-CH₃), 1.96 (3H, s, 9-CH₃), 2.50 (1H, m, 5'-H), 2.60 (3H, s, 14-COCH₃), 2.78 (3H, s, 10-COCH₃), 4.19 (1H, d, *J*=16 Hz, 4-H), 4.28 (1H, d, *J*=16 Hz, 4-H), 5.85 (1H, d, *J*=9.2 Hz, 4'-H), 6.24 (1H, d, *J*=14.6 Hz, 1'-H), 7.38 (1H, d, *J*=14.6 Hz, 2'-H), 7.68 (1H, s, 1-H). ¹³C NMR (75 MHz, CDCl₃) δ 11.903 (7'-C), 12.419 (9-CH₃), 14.937 (10-COCH₃), 19.982 (9'-C), 25.916 (8'-C), 29.874 (6'-C), 30.428 (14-COCH₃), 35.298 (5'-C), 41.958 (4-C), 84.705 (7-C), 122.649 (1'-C), 125.403 (4a-C), 128.938 (1-C), 128.991 (5-C), 130.379 (14-C), 131.737 (3'-C), 140.483 (6-C), 141.940 (1a-C), 142.668 (10-C), 150.724

(2'-C), 152.348 (4'-C), 152.909 (8-C), 166.300 (15-C), 189.116 (11-C), 193.190 (3-C), 200.686 (14-COCH₃), 201.284 (10-COCH₃).

Inhibition Experiments

The inhibitory activities against gp120-CD4 binding of these products were determined by enzyme-linked immunosorbent assay (ELISA) using recombinant soluble CD4 and recombinant gp120 as described by GILBERT, M., *et al.*⁷⁾ The reagents CD4 and gp120 and anti-CD4 used in the assay were generous gifts from Genentech Inc. (CA, U.S.A.).

References

- 1) WHALLEY, W. B.; G. FERGUSON, W. C. MARSH & R. J. RESTIVO: The chemistry of fungi. Part LXVIII. The absolute configuration of (+)-sclerotiorin and of the azaphilones. *J. Chem. Soc. Perkins Trans. I*, 1976: 1366~1369, 1976
- 2) CURTIN, T. P. & J. REILLY: Sclerotiorine, C₂₀H₂₀O₅Cl, a chlorine-containing metabolic product *Penicillium sclerotirium* Van Beyma. *Biochem. J.* 34: 1419~1421, 1940
- 3) ŌMURA, S.; H. TANAKA, K. MATSUZAKI & R. MASUMA: Isochromophilones I and II, novel inhibitors against gp120-CD4 binding from *Penicillium* sp. *J. Antibiotics* 46: 1908~1911, 1993
- 4) MATSUZAKI, K.; H. IKEDA, R. MASUMA, H. TANAKA & S. ŌMURA: Isochromophilones I and II, inhibitors against gp120-CD4 binding produced by *Penicillium multicolor* FO-2338. *J. Antibiotics* 48: 703~713, 1993
- 5) YAMASHITA, M.; Y. TANAKA, A. ARITA & M. NISHIDA: Sodium hydrogen telluride, a new reagent for the hydrogen of carbon-carbon double bonds. *J. Org. Chem.* 59: 3500~3502, 1994
- 6) RAMASAMY, K.; S. K. KALYANASUNDARAM & P. SHANMUGAM: The reduction of sodium hydrogen telluride with α,β-unsaturated carbonyl compounds synthesis. 545~547, 1978
- 7) GILBERT, M.; J. KIRIHARA & J. MILLS: Enzyme-linked immunoassay for human immunodeficiency virus type 1 envelope glycoprotein 120. *J. Clin. Microbiol.* 29: 142~147, 1991